A new member of family Parvoviridae, human parvovirus 4 (PARV4), was identifi ed in plasma of an injection drug user (IDU) with unexplained fatigue, headaches, fever, night sweats, nausea, and diarrhea (1) . In PCR studies of blood and postmortem tissues, virus was detected mainly in persons with histories of injection drug use (2) (3) (4) (5) . A recent PARV4 immunoglobulin (Ig) G study also showed higher prevalence of antibodies to PARV4 in IDUs and HIV-positive persons who had hemophilia than in HIV-positive men who have sex with men (6) . The clinical role of this virus is unknown.
We report virus-like particle-based comprehensive serodiagnosis for PARV4 and determine its occurrence in Finland in 3 diverse population groups. In the highest prevalence group, we comparatively analyzed PARV4 IgGpositive and IgG-negative persons for sociodemographic and behavioral background factors and symptoms by using an HIV risk factor database (7).
The Study
Group 1 (low risk) comprised 115 university students (1 serum sample/student). Group 2 (high risk) comprised 78 HIV IgG-positive IDUs from the Helsinki Cohort Study (8) (151 plasma samples, 1-7 samples/person). Group 3 (high risk) comprised 200 hepatitis C virus (HCV) IgGpositive patients (1 sample/person). Informed consent was obtained from persons in groups 1 and 2 and from 2 patients with primary infections in group 3. The study was reviewed and approved by the Helsinki University Central Hospital Ethics Committee (#281/13/03/01/09 and #469/2001).
Four genomic regions of open reading frame 2 of PARV4 genotype 1 (AY622943) were cloned for baculovirus expression by using PARV4 PCR-positive plasma (1) as initial template. The clone with nt region 3137-5122 (AY622943) and infectivity was constructed with primers PARV4EcoRI_3137: 5′-TATGAATT CATGATTGAGCATGGGG-3′ and PARV4EagI_5122: 5′-TACGGCCGTTACAGCAAATGAGAATAA-3′.
Protein expression and virus-like particle purifi cation were conducted as for human bocavirus (HBoV) (9) . Sodium dodecyl sulfate-polyacrylamide gel electrophoresis identifi ed a 73-kDa protein ( Figure 1, panel A) , which was immunoreactive by Western blotting (10) with 5 known PARV4 IgG-positive serum samples (6) but not with negative serum samples ( Figure 1, panel B) . Electron microscopy showed spherical particles ≈25 nm in diameter (Figure 1 , panel C) that resembled those seen in vivo (11) . The capsid protein region is 109 aa longer (N terminally) than that reported by Sharp et al. (6) ; both constructs assembled into capsids.
PARV4 IgG enzyme immunoassay (EIA) was conducted as for HBoV (9) . Specifi c results were obtained by subtracting antigen-free background levels. For IgM EIA, a μ-capture format was used (9) . IgG and IgM cutoff values, obtained from group 1 absorbances (mean + 4 × SD), were 0.141 and 0.205, respectively. IgG-avidity EIA was conducted as for HBoV (method A) (12); cutoff values for high and low avidity were 25% and 15%, respectively.
None of the 115 students (group 1) were PARV4 IgG positive, and 1 (0.9%) of 115 was weakly IgM positive ( Previous samples were available for 2 of the IgM-positive patients (A and B) in group 3. These samples showed seroconversion for IgG and an increase in IgG (Table 1) .
PARV4 IgG avidity was determined in all persistently (>1 year) IgG-positive persons in group 2 (n = 29). Twenty-eight persons showed high IgG avidity, and 1 showed borderline IgG avidity. All 4 IgG-positive persons had high-avidity IgG, which indicated previous immunity.
In group 3, a second sample from patient A, who showed seroconversion for IgG showed borderline IgG avidity. Patient B showed low IgG avidity in both samples (Table 1) .
Groups 2 and 3 were also analyzed for PARV4 DNA by qualitative PCR (13) as modifi ed (94°C for 10 min; 45 cycles at 94°C for 20s, 51°C or 56°C for 20s, and 72°C for 20s; and extension at 72°C for 7 min). Amplicons were subjected to electrophoresis and sequenced. In group 2, all 151 serum samples were PCR negative. In group 3, two patients (A and B) were PCR positive (Table 1) .
PARV4 IgG-positive and IgG-negative IDUs (group 2) were compared for demographic and clinical characteristics. PARV4 IgG-positive persons reported more injection of drugs, persistent (>10 y) injection, and lending of injection equipment (Table 2) . They also had a more frequent history of imprisonment and unemployment and were less educated. No differences were seen between PARV4 IgG-positive and IgG-negative persons with any symptoms (fever, tiredness, nocturnal sweating, cough, diarrhea, shortness of breath, swallowing complaints, muscle weakness, dizziness, skin abscesses or herpetic lesions, loss of eyesight, or headache) during 6 months before being interviewed.
Conclusions
We developed IgG-, IgM-, and IgG-avidity-based PARV4 serodiagnostic procedures; studied high-prevalence cohorts by PCR; and analyzed HIV-infected IDUs for demographic and clinical correlations with PARV4 IgG positivity. Among healthy university students, none had PARV4 IgG, which is consistent with low baseline IgG prevalences of 0% and 2.8% for another EIA (6) . The PARV4 IgG seroprevalence of 78% among HIV-infected IDUs represents a high incidence of PARV4, which refl ects the lengthy history of drug use among socially marginalized IDUs during an HIV outbreak in Finland (7). Two HCV-infected patients had PARV4 primary infections, as shown by increasing IgG levels, detectable IgM, low or borderline IgG avidity, and viral DNA in serum. These 4 fi ndings are presented as diagnostic criteria for PARV4 primary infection. As estimated by known kinetics of B19 virus diagnostics (14) , these 2 PARV4 infections probably occurred in 2005. During that time, neither patient had contacted local healthcare providers. Conversely, these 2 patients used intravenous drugs daily, and might not have sought medical care unless they were severely ill.
Because PARV4 IgG seroprevalence in group 1 was 0% in this study, in contrast to prevalences of 60% for B19 (12) and 96% for HBoV (9) in the same students, serologic cross-reactivity between PARV4 and the other human parvoviruses appears highly unlikely. Amino acid sequence similarity is <30% between B19 and PARV4 and ≈40% between HBoV and PARV4.
PCR-negative results for group 2, including 4 patients who were IgM positive, are evidence against viremic primary, chronic, and recurrent PARV4 infections. However, because of the relatively low sensitivity of this PCR, the data do not rule out low levels of viral DNA in blood.
Analysis of HIV-infected IDUs supports the view that in northern Europe PARV4 is primarily a blood-borne virus. No differences were seen for factors related to sexual activity. However, our sample size was too small to make this conclusion. In a recent PCR study, PARV4 genotype 
